Travere Therapeutics Inc (TVTX) Stock AnalysisTVTXTravere Therapeutics Inc

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Travere Therapeutics Inc is currently a hold. The stock is priced at $50.08, which is significantly below the analyst price targets ranging from $75 to $89, indicating potential upside. However, the RSI is at 31.377, suggesting the stock is oversold, and the forward P/E ratio is 39.84, indicating high valuation expectations. The main risk is the recent net loss of $34.79 million in Q2 2026, which is higher than the previous year's loss, highlighting ongoing financial challenges.